Schering-Plough Hopes To Enhance Confidence In Vytorin/Zetia With Monthly Rx Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm feeling impact on sales from Vytorin study results.
You may also be interested in...
Vytorin Continues To Grow Globally As Schering Seeks Ways To ENHANCE U.S. Sales
Cholesterol franchise is up 6 percent overall as Zetia and Vytorin prescription sales drop 5 percent in the U.S. in the wake of negative trial results.
Vytorin Continues To Grow Globally As Schering Seeks Ways To ENHANCE U.S. Sales
Cholesterol franchise is up 6 percent overall as Zetia and Vytorin prescription sales drop 5 percent in the U.S. in the wake of negative trial results.
Vytorin, Zetia, Other Combos In Spotlight At ACC Conference
Highlights of the upcoming American College of Cardiology conference include ENHANCE data and updates on ACCOMPLISH and ONTARGET trials.